Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 9 Lymphoma, Non-Hodgkin 9 Lymphoma, B-Cell 5 Arthritis, Rheumatoid 5 Solid Tumors 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma 4 Carcinoma, Non-Small-Cell Lung 4 Recurrence 3 Colorectal Neoplasms 3 Ovarian Neoplasms 2 Lymphoma, Follicular 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Fallopian Tube Neoplasms 2 Breast Neoplasms 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Spondylitis, Ankylosing 1 Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 Mesothelioma 1 Melanoma 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Esophageal Neoplasms 1

Interventions

tisagenlecleucel 8 Cyclophosphamide 7 fludarabine 5 blinatumomab 5 aflibercept 4 ibrutinib 2 epratuzumab 2 Vincristine 2 Radioimmunodetection 2 Methotrexate 2 MLN 8237 2 Inotuzumab Ozogamicin 2 Dexamethasone 2 tocilizumab 1 tafasitamab 1 siltuximab 1 sepantronium 1 ruxolitinib 1 relatlimab 1 pembrolizumab 1 pegaspargase 1 ontuxizumab 1 obinutuzumab 1 loncastuximab tesirine 1 forodesine 1 fludarabine phosphate 1 fiu protein, E coli 1 exatecan 1 brexucabtagene autoleucel 1 asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Burkitt Lymphoma × tocilizumab × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡